My bibliography
Save this item
Generic entry, price competition, and market segmentation in the prescription drug market
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Herr, A. & Suppliet, M., 2011.
"Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany,"
Health, Econometrics and Data Group (HEDG) Working Papers
11/18, HEDG, c/o Department of Economics, University of York.
- Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-021, Tilburg University, Tilburg Law and Economic Center.
- Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-040, Tilburg University, Center for Economic Research.
- Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013.
"The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity,"
NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 243-271,
National Bureau of Economic Research, Inc.
- Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013. "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity," NBER Working Papers 19487, National Bureau of Economic Research, Inc.
- Castanheira, Micael & Ornaghi, Carmine & Siotis, Georges, 2019.
"The unexpected consequences of generic entry,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2019. "The Unexpected Consequences of Generic Entry," ULB Institutional Repository 2013/298643, ULB -- Universite Libre de Bruxelles.
- Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
- de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges, 2013.
"Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 268-285.
- Siotis, Georges & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2010. "Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?," CEPR Discussion Papers 8076, C.E.P.R. Discussion Papers.
- Glenn Ellison & Sara Fisher Ellison, 2011.
"Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration,"
American Economic Journal: Microeconomics, American Economic Association, vol. 3(1), pages 1-36, February.
- Glenn Ellison & Sara Fisher Ellison, 2007. "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration," NBER Working Papers 13069, National Bureau of Economic Research, Inc.
- Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021.
"Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions,"
Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
- Farasat A.S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2019. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2016-01v3, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018.
"Common ownership and market entry: Evidence from the pharmaceutical industry,"
Working Papers of Department of Management, Strategy and Innovation, Leuven
623896, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
- Melisa Newham & Jo Seldeslachts & Albert Banal-Estañol, 2018. "Common ownership and market entry: Evidence from the pharmaceutical industry," Economics Working Papers 1612, Department of Economics and Business, Universitat Pompeu Fabra.
- Albert Banal-Estañol & Melissa Newham & Jo Seldeslachts, 2018. "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers 1042, Barcelona School of Economics.
- Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018. "Common Ownership and Market Entry: Evidence from Pharmaceutical Industry," Discussion Papers of DIW Berlin 1738, DIW Berlin, German Institute for Economic Research.
- Newham, M. & Seldeslachts, J. & Banal-Estanol, A., 2018. "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers 18/03, Department of Economics, City University London.
- Skipper, Niels & Vejlin, Rune, 2015.
"Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data,"
Social Science & Medicine, Elsevier, vol. 130(C), pages 204-215.
- Niels Skipper & Rune Vejlin, 2013. "Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data," Economics Working Papers 2013-05, Department of Economics and Business Economics, Aarhus University.
- Aljoscha Janssen, 2022. "Price dynamics of Swedish pharmaceuticals," Quantitative Marketing and Economics (QME), Springer, vol. 20(4), pages 313-351, December.
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014.
"Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark,"
Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
- Ulrich Kaiser & Susan J. Mendez & Thomas Rønde, 2010. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," CIE Discussion Papers 2010-01, University of Copenhagen. Department of Economics. Centre for Industrial Economics.
- Kaiser, Ulrich & Méndez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," IZA Discussion Papers 7248, Institute of Labor Economics (IZA).
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas, 2010. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," ZEW Discussion Papers 10-062, ZEW - Leibniz Centre for European Economic Research.
- Ulrich Kaiser & Susan J. Méndez & Thomas Rønde & Hannes Ullrich, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," Working Papers 330, University of Zurich, Department of Business Administration (IBW).
- Kaiser, Ulrich & Méndez, Susan & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79937, Verein für Socialpolitik / German Economic Association.
- A. Yeşim Orhun & Sriram Venkataraman & Pradeep K. Chintagunta, 2016. "Impact of Competition on Product Decisions: Movie Choices of Exhibitors," Marketing Science, INFORMS, vol. 35(1), pages 73-92, January.
- Mark Armstrong & John Vickers, 2022.
"Patterns of Competitive Interaction,"
Econometrica, Econometric Society, vol. 90(1), pages 153-191, January.
- Armstrong, Mark & Vickers, John, 2019. "Patterns of Competitive Interaction," MPRA Paper 95336, University Library of Munich, Germany.
- Mark Armstrong & John Vickers, 2021. "Patterns of Competitive Interaction," Economics Series Working Papers 936, University of Oxford, Department of Economics.
- Armstrong, Mark & Vickers, John, 2021. "Patterns of Competitive Interaction," MPRA Paper 108398, University Library of Munich, Germany.
- Armstrong, Mark & Vickers, John, 2019. "Patterns of Competitive Interaction," CEPR Discussion Papers 13821, C.E.P.R. Discussion Papers.
- armstrong, Mark & Vickers, John, 2020. "Patterns of competitive interaction," MPRA Paper 102789, University Library of Munich, Germany.
- Birg, Laura, 2019. "Substitution Policy and Generic Competition," University of Göttingen Working Papers in Economics 241, University of Goettingen, Department of Economics, revised 2019.
- Siotis, Georges & Ornaghi, Carmine & Castanheira, Micael, 2019.
"Market Definition and Competition Policy Enforcement in the Pharmaceutical Industry,"
CEPR Discussion Papers
14035, C.E.P.R. Discussion Papers.
- Georges Siotis & Carmine Ornaghi & Micael Castanheira De Moura, 2020. "Market Definition and Competition Policy Enforcement in the Pharmaceutical Industry," Working Papers ECARES 2020-49, ULB -- Universite Libre de Bruxelles.
- Georges Siotis & Carmine Ornaghi & Micael Castanheira, 2023.
"Evolving market boundaries and competition policy enforcement in the pharmaceutical industry,"
European Journal of Law and Economics, Springer, vol. 55(2), pages 313-348, April.
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2023. "Evolving Market Boundaries and Competition Policy Enforcement in the Pharmaceutical Industry," ULB Institutional Repository 2013/353440, ULB -- Universite Libre de Bruxelles.
- Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
- Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
- Dag Dalen & Kari Furu & Marilena Locatelli & Steinar Strøm, 2011.
"Generic substitution: micro evidence from register data in Norway,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(1), pages 49-59, February.
- Dalen Gag Morten & Furu Kai & Locatelli Marilena & Strom Steinar, 2009. "Generic substitution. Micro evidence from register data in Norway," Department of Economics and Statistics Cognetti de Martiis. Working Papers 200901, University of Turin.
- Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
- Granlund, David & Bergman, Mats A., 2018. "Price competition in pharmaceuticals – Evidence from 1303 Swedish markets," Journal of Health Economics, Elsevier, vol. 61(C), pages 1-12.
- Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2016.
"Reference pricing with endogenous generic entry,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 312-329.
- Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2015. "Reference pricing with endogenous generic entry," Discussion Paper Series in Economics 4/2015, Norwegian School of Economics, Department of Economics.
- Kurt R. Brekke & Chiara Canta & Odd Rune Straume, 2015. "Reference pricing with endogenous generic entry," NIPE Working Papers 2/2015, NIPE - Universidade do Minho.
- Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.
- Luke M. Olson & Brett W. Wendling, 2018. "Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 139-172, August.
- Barenji, Reza Vatankhah & Hariry, Reza Ebrahimi & Demirkol, Denizhan & Daim, Tugrul U., 2024. "Research landscape analysis for quality in Pharma 4.0 era," Technology in Society, Elsevier, vol. 76(C).
- Carneiro, Livia Mendes & Eid Junior, William & Yoshinaga, Claudia Emiko, 2022. "The implications of passive investments for active fund management: International evidence," Global Finance Journal, Elsevier, vol. 53(C).
- Carl Rudolf Blankart & Tom Stargardt, 2017. "Preferred supplier contracts in post-patent prescription drug markets," Health Care Management Science, Springer, vol. 20(3), pages 419-432, September.
- Frank R. Lichtenberg, 2021. "Are drug prices subject to creative destruction? Evidence from the US, 1997–2017," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1910-1932, August.
- Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013.
"Pharmaceutical followers,"
International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553.
- Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley, 2013. "Pharmaceutical Followers," NBER Working Papers 19522, National Bureau of Economic Research, Inc.
- Siotis, Georges & Castanheira, Micael & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2017. "The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma," CEPR Discussion Papers 11813, C.E.P.R. Discussion Papers.
- Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
- Sarmah, Archita & De Giovanni, Domenico & De Giovanni, Pietro, 2020. "Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies," European Journal of Operational Research, Elsevier, vol. 282(3), pages 1053-1069.
- Luiz Andrade & Catherine Sermet & Sylvain Pichetti, 2016.
"Entry time effects and follow-on drug competition,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 45-60, January.
- Luiz Flavio Andrade, 2011. "Entry time effects and follow on drug competition," Post-Print halshs-00658247, HAL.
- Luiz Flavio Andrade, 2012. "Entry Time Effects and Follow-on Drugs Competition," Working Papers DT49, IRDES institut for research and information in health economics, revised Jun 2012.
- Luiz Flavio Andrade & Catherine Sermet & Sylvain Pichetti, 2016. "Entry time effects and follow-on drug competition," Post-Print halshs-01156509, HAL.
- Panattoni, Laura E., 2011. "The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms," Journal of Health Economics, Elsevier, vol. 30(1), pages 126-145, January.
- Suppliet, Moritz & Herr, Annika, 2016.
"Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets,"
Other publications TiSEM
4d692f0e-8577-4392-b413-2, Tilburg University, School of Economics and Management.
- Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.
- Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-021, Tilburg University, Tilburg Law and Economic Center.
- Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Discussion Paper 2016-040, Tilburg University, Center for Economic Research.
- Whaley, Christopher M. & Brown, Timothy T., 2018. "Firm responses to targeted consumer incentives: Evidence from reference pricing for surgical services," Journal of Health Economics, Elsevier, vol. 61(C), pages 111-133.
- Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.
- Toshiaki Iizuka, 2012. "Physician Agency and Adoption of Generic Pharmaceuticals," American Economic Review, American Economic Association, vol. 102(6), pages 2826-2858, October.
- de Haas, Samuel & Herold, Daniel & Schäfer, Jan Thomas, 2022. "Entry deterrence due to brand proliferation: Empirical evidence from the German interurban bus industry," International Journal of Industrial Organization, Elsevier, vol. 83(C).
- Aida Isabel Tavares, 2017. "Generic substitution policy, an incentive approach," Computational and Mathematical Organization Theory, Springer, vol. 23(2), pages 199-220, June.
- Janssen, Aljoscha, 2020. "Price Dynamics of Swedish Pharmaceuticals," Working Paper Series 1325, Research Institute of Industrial Economics.
- Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
- Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011.
"Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008,"
CESifo Working Paper Series
3441, CESifo.
- Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
- Costa-Font, Joan & McGuire, Alistair & Varol, Nebibe, 2014. "Price regulation and relative delays in generic drug adoption," Journal of Health Economics, Elsevier, vol. 38(C), pages 1-9.
- Herr, Annika, 2012. "Rationalisierung und Wettbewerb im Arzneimittelmarkt," DICE Ordnungspolitische Perspektiven 31, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Farasat A. S. Bokhari & Gary M. Fournier, 2013.
"Entry in the ADHD drugs market: Welfare impact of generics and me-too's,"
Journal of Industrial Economics, Wiley Blackwell, vol. 61(2), pages 339-392, June.
- Farasat A.S. Bokhari & Gary M. Fournier, 2009. "Entry in the ADHD drugs market: Welfare impact of generics and me-toos," Working Papers wp2009_05_01, Department of Economics, Florida State University.
- Julen Castillo‐Apraiz & Jesus Matey, 2020. "Customizing competitive strategy to entry timing: Implications for firm performance in the pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 41(6), pages 976-985, September.
- Cristina Zerbini & Donata Tania Vergura & Beatrice Luceri, 2017. "Consumers? intention to buy generic drugs: Evidences from the Italian setting," MERCATI & COMPETITIVIT?, FrancoAngeli Editore, vol. 2017(1), pages 159-176.
- Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
- Furu, Kari & Dalen, Dag Morten & Locatelli, Marilena & Strøm, Steinar, 2008. "Generic Substitution," Memorandum 11/2008, Oslo University, Department of Economics.
- Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.
- Cici McNamara & Natalia Serna, 2022. "The impact of a national formulary expansion on diabetics," Health Economics, John Wiley & Sons, Ltd., vol. 31(11), pages 2311-2332, November.